Oncology Central

TET enzymes as oxygen-dependent tumor suppressors: exciting new avenues for cancer management


Oncogenesis occurs through the acquisition of mutations and the subsequent selection of those that confer growth advantages. Apart from these genetic changes, tumors are also epigenetically distinct from their tissue of origin, as they frequently display a global DNA hypomethylation and a focal hypermethylation at tumor suppressor gene promoters. Similar to mutations, such epigenetic aberrations can inactivate associated genes and contribute to oncogenesis. The source of these epigenetic alterations is, however, often unknown.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.